Table 3.
CVD mortality rates per 100 000 person-years in three population-based cohort studies in Iran, ages 40–80 years
| 10-year CVD mortality, n | Person-years | Crude mortality rate (95% CI) | Direct standardised mortality rate (95% CI)* | Direct standardised mortality rate (95% CI)† |
Multivariable adjusted HRs‡ | P values | |
| Total | |||||||
| TLGS | 145 | 49 043 | 296 (251 to 348) | 328 (271 to 384) | 393 (326 to 461) | 1 | – |
| ICS | 132 | 38 434 | 344 (290 to 407) | 343 (283 to 402) | 409 (337 to 480) | 1.10 (0.86–1.39) | 0.450 |
| GCS | 1677 | 394 364 | 425 (405 to 446) | 542 (514 to 570) | 629 (595 to 663) | 2.00 (1.68–2.39) | <0.001 |
| Women | |||||||
| TLGS | 44 | 27 045 | 163 (121 to 219) | 204 (138 to 270) | 263 (171 to 355) | 1 | – |
| ICS | 52 | 19 641 | 265 (202 to 347) | 283 (204 to 363) | 326 (233 to 420) | 1.38 (0.92–2.07) | 0.118 |
| GCS | 778 | 299 046 | 339 (317 to 364) | 463 (425 to 500) | 571 (498 to 645) | 2.65 (1.95–3.60) | <0.001 |
| Men | |||||||
| TLGS | 101 | 21 998 | 459 (378 to 558) | 452 (360 to 543) | 543 (434 to 652) | 1 | – |
| ICS | 80 | 18 793 | 426 (342 to 530) | 402 (313 to 492) | 482 (376 to 589) | 0.97 (0.72–1.30) | 0.820 |
| GCS | 899 | 165 318 | 544 (509 to 581) | 622 (579 to 664) | 776 (696 to 856) | 1.72 (1.38–2.14) | <0.001 |
Shahroud Eye Cohort Study was not included in this part of estimations since all of the participants were under 65 years.
*Age adjustment based on Iranian national census,
†Age adjustment based on ‘European’ standard population.
‡HRs based on Cox model adjusted by age, sex, hypertension, smoking, self-reported diabetes and body mass index.
CVD, cardiovascular disease; GCS, Golestan Cohort Study (phase 1); ICS, Isfahan Cohort Study; TLGS, Tehran Lipid and Glucose Study.